INTRODUCTION {#S1}
============

Medulloblastoma (MB) is the most common malignant brain tumor in children. It usually originates from the cerebellum, but it may spread to other parts of the central nervous system (CNS) ([@R17]; [@R49]). Conventional treatment consists of a combined modality approach including surgery, radiation therapy, and chemotherapy, which often cause delayed complications in most patients, such as endocrine disorders and cognitive deficits. Clinical trials and research efforts are now focused on attempts to decrease treatment toxicity while maintaining a high cure rate in MB patients ([@R40]; [@R42]).

Human MB consists of at least four subgroups: hedgehog (Hh), Wnt, group 3, and group 4 ([@R39]; [@R55]). Among these, Hh-MB accounts for at least 30% of human MB. Inactivating mutations in *Patched 1* (*Ptch1*), the antagonizing receptor for Hh ligand, leads to aberrant activation of the Hh pathway, with increased transcription of Hh pathway target genes, including *Ptch2*, *Gli1*, and *Gli2* ([@R24]). *Ptch1* heterozygous mice (*Ptch1*^+/−^) in which one allele of the *Ptch1* gene was replaced with β-galactosidase develop MB in their cerebella at \~30 weeks of age ([@R19]). *Ptch1*^+/−^ mice are widely used in basic research and preclinical studies of Hh-MB. Group 3 MB represents the most aggressive MB type, exhibiting amplification or overexpression of the MYC oncogene ([@R3]). Previous studies have demonstrated that cerebellar granule neuron precursors (GNPs) can serve as cells of origin for both Hh-MB and group 3 MB ([@R26]; [@R44]; [@R53]; [@R65]).

As the most abundant neuronal progenitors in the brain, GNPs proliferate extensively in the external germinal layer (EGL) at the surface of the cerebellum. After that, GNPs permanently exit the cell cycle and start to differentiate in the deep part of the EGL. As they differentiate, GNPs continue to migrate to their final destination, the internal granule layer (IGL). In the IGL, GNPs become fully differentiated and mature ([@R18]). The differentiation of GNPs is under a precise spatial/temporal control during cerebellar development.

While the differentiation of neural stem/progenitor cells has been well studied, it still remains unclear whether tumor cells derived from neuronal progenitors can undergo differentiation. By performing single-cell RNA sequencing (scRNA-seq) on a mouse model of MB, we have identified a population of tumor cells that has lost its proliferative capacity and tumorigenic potential and appears to be undergoing differentiation. Resembling GNPs, MB cells extensively express genes associated with neuronal differentiation and maturation as they differentiate. The differentiation of MB cells is regulated by the NeuroD1 expression, and forced expression of NeuroD1 induces differentiation of tumor cells from Hh-MB, indicating that the differentiation overrides oncogenic mutations in MB cells. In the majority of tumor cells, NeuroD1 enhancer and promoter are repressed by trimethylation of histone 3 lysine-27 (H3K27me3). Importantly, pharmacological inhibition of the histone lysine methyltransferase EZH2 prevents H3K27 trimethylation, resulting in increased NeuroD1 expression and enhanced tumor cell differentiation, which consequently reduces tumor growth. These studies demonstrate that MB cells retain the ability to undergo differentiation and pave the way for therapies that target this process.

RESULTS {#S2}
=======

scRNA-Seq Reveals a Population of Differentiated MB Cells {#S3}
---------------------------------------------------------

To examine tumor cell heterogeneity in MB, we performed scRNA-seq on cells dissociated from MB tissue in *Ptch1*^+/−^ mice. Data from a total of 9,164 cells that met quality control criteria (average 2,130 unique genes per cell) were used for transcriptomic analysis. To define cell identities and subpopulations, we performed principal-component analysis (PCA) and t-stochastic neighbor embedding (tSNE) analysis. These analyses identified transcriptionally distinct cell clusters corresponding to six broad categories ([Figure 1A](#F1){ref-type="fig"}). Approximately 93% of total analyzed transcriptomes represented tumor cells, distinguished by expression of genes specific for Hh-MB such as *Zic1* and *Barhl1* ([@R32]; [@R48]; [@R68]) ([Figure 1B](#F1){ref-type="fig"}). Based on the expression of well-established markers, we also identified major components of the MB micro-environment, including astrocytes (*Gfap*, *Fabp7*, and *Slc1a3*), oligodendrocytes (*Cspg4*, *Pdgfra*, and *Cntn1*), and microglial cells (*Aif1*, *Cx3cr1*, and *Adgre1*) ([Figures 1C](#F1){ref-type="fig"} and [1D](#F1){ref-type="fig"}).

Within the tumor cell population, we identified three major clusters of cells: (1) dividing tumor cells that express high levels of genes associated with the cell cycle/division (*Cdk1*, *Ccna2*, and *Cenpf*) and elevated levels of Hh target genes such as *Gli1*, *Gli2*, and *Ptch2*; (2) quiescent tumor cells, in which cell-cycle/division genes have been downregulated but Hh pathway target genes remain activated; and (3) cells expressing low levels of cell-cycle/division genes and low levels of Hh target genes but elevated expression of genes related to neuronal differentiation, including *Cntn2*, *Pax6*, *NeuroD1*, *Tubb3*, and *Gap43* ([Figures 1C](#F1){ref-type="fig"} and [1D](#F1){ref-type="fig"}). We speculated that the latter population represented tumor cells spontaneously undergoing differentiation. Quiescent, dividing, and differentiated cells accounted for 41%, 30%, and 22% of the total cell population, respectively ([Figure 1E](#F1){ref-type="fig"}). Approximately 7% of the total cell population was composed of stromal cells, including astrocytes, microglia, and oligodendrocytes. Thus, a subset of differentiated cells was found in MB tissue based on scRNA-seq analysis.

t-SNE plots revealed that neuronal differentiation genes, including *Pax6*, *Cntn2*, *NeuroD1*, and *Tubb3*, were enriched in those differentiated MB cells ([Figure 1F](#F1){ref-type="fig"}), whereas the expression of genes associated with cell division, including *Ccna2*, *Ccnb1*, *Cdk1*, and *Cenpf*, was overall downregulated in differentiated tumor cells ([Figure 1G](#F1){ref-type="fig"}). We further analyzed scRNA-seq data obtained from human MB consisting of all four groups (Hh, Wnt, group 3, and group 4) ([@R23]). Consistent with the previous report ([@R23]), the four MB groups were well separated based on the genetic profiles of tumor cells ([Figure 1H](#F1){ref-type="fig"}). The distinct population of differentiated tumor cells was readily identified in Hh-group MB based on the elevated expression of neuronal differentiation genes (*Pax6*, *Cntn2*, *NeuroD1*, and *Tubb3*) ([Figure 1I](#F1){ref-type="fig"}). Similar to those differentiated MB cells from *Ptch1*^+/−^ mice, expression levels of cell-cycle genes (*Ccna2*, *Ccnb1*, *Cdk1*, and *Cenpf*) were decreased in differentiated tumor cells in human MB. These data suggest that the differentiation of tumor cells was also present in human MB. All these data confirm that MB cells in both human and mouse can differentiate *in vivo*.

Differentiated MB Cells Are Not Proliferative or Tumorigenic {#S4}
------------------------------------------------------------

One gene highly expressed by differentiated tumor cells was *Cntn2* ([Figures 1C](#F1){ref-type="fig"} and [1F](#F1){ref-type="fig"}), which encodes Tag1, a cell-surface glycoprotein associated with the differentiation and migration of neuronal progenitors ([@R63]). Consistent with our scRNA-seq findings, immunofluorescent staining indicated that a proportion of tumor cells in MB tissue expressed Tag1 ([Figures 2A](#F2){ref-type="fig"}--[2C](#F2){ref-type="fig"}) but were Ki67^−^, suggesting they were not dividing. Moreover, Tag1^+^ cells also expressed MAP2, a marker for neuronal maturation ([@R10]). These data suggest that Tag1-expressing cells represent differentiated MB cells. To further determine whether Tag1^+^ cells represent a differentiated subset, we isolated Tag1^+^ cells from *Ptch1*^+/−^ mice by fluorescence-activated cell sorting (FACS) using an antibody against Tag1. As shown in [Figure 2D](#F2){ref-type="fig"}, \~21% of tumor cells were positive for Tag1. Purified Tag1^+^ and Tag1^−^ cells were plated *in vitro*, and pulse-labeled with bromodeoxyuridine (BrdU) for 2 h before being harvested for immunocytochemistry ([Figures 2E](#F2){ref-type="fig"} and [2F](#F2){ref-type="fig"}). More than 60% of Tag1^−^ cells were found to be positive for BrdU, whereas less than 10% of Tag1^+^ cells were BrdU positive ([Figure 2G](#F2){ref-type="fig"}), suggesting that Tag1^+^ cells were not actively dividing. We next transplanted Tag1^+^ and Tag1^−^ cells intracranially into *CB17/SCID* mice to examine the tumorigenicity of these two cell populations ([@R31]; [@R33]). As shown in [Figure 2H](#F2){ref-type="fig"}, Tag1^−^ cells gave rise to tumors in *CB17/SCID* mice with 100% penetrance (median survival, 52 days), whereas no tumors arose from Tag1^+^ cells. The above data suggest that Tag1^+^ cells have lost proliferative and tumorigenic potential.

Tumors derived from transplantation of Tag1^−^ cells contained a population of Tag1^+^ cells comparable to the \~20% of Tag1^+^ cells found in tumors of *Ptch1*^+/−^ mice, suggesting that proliferating tumor cells can undergo spontaneous differentiation during tumor formation. To further examine this spontaneous differentiation, we lineage traced tumor cells by crossing *Ptch1*^+/−^ mice with *Math1-CreER*^*T2*^*/Rosa-GFP* mice in which tumor cells (Math1^+^) permanently express GFP upon tamoxifen treatment ([@R65]). At 20 weeks of age, when *Math1-CreER*^*T2*^*/Rosa-GFP/Ptch1*^+/−^ mice exhibited signs of intracranial pressure such as ataxia and domed heads, they were treated with tamoxifen by oral gavage. 1 week after tamoxifen treatment, mouse brains were harvested for immunohistochemistry, following intraperitoneal (i.p.) injection of EdU 2 h prior to the sacrifice. As shown in [Figure 2I](#F2){ref-type="fig"}, robust expression of GFP was observed in the cerebellar tumor developed from a *Math1-CreER*^*T2*^*/Rosa-GFP/Ptch1*^+/−^ mouse. Differentiated cells (Tag1^+^) as well as proliferative cells (EdU^+^) were all found to be positive for GFP ([Figures 2J](#F2){ref-type="fig"} and [2K](#F2){ref-type="fig"}), indicating that they were all derived from tumor cells. Differentiated cells (Tag1^+^) and EdU^+^ cells were mutually exclusive, confirming that differentiated cells were not dividing ([Figure 2L](#F2){ref-type="fig"}).

MB Cells Resemble GNPs in Their Differentiation {#S5}
-----------------------------------------------

Having identified a population of differentiated tumor cells, we next sought to compare tumor cell differentiation with the differentiation of GNPs, the normal cells from which tumors are thought to originate ([@R53]; [@R65]). After proliferating in the superficial EGL (sEGL), GNPs exit the cell cycle and start to differentiate as they migrate into the deep part of the EGL (dEGL). Upon migration to the IGL, GNPs become fully differentiated ([Figure 3A](#F3){ref-type="fig"}). As shown in [Figure 3B](#F3){ref-type="fig"}, Tag1 expression was located in cerebellar dEGL, whereas the sEGL was dominated by dividing GNPs (Ki67^+^), suggesting that Tag1 expression is initiated as GNPs exit the cell cycle and begin to differentiate in the dEGL. Tag1 expression appears to be lost before GNPs undergo terminal differentiation, since it is absent from mature granule neurons (expressing βIII-tubulin) in the IGL ([Figure 3C](#F3){ref-type="fig"}). The above expression pattern of Tag1 during GNP development was further confirmed by EdU chasing experiments and lineage-tracing assays ([Figures S1A](#SD1){ref-type="supplementary-material"}--[S1H](#SD1){ref-type="supplementary-material"}), consistent with previous reports ([@R14]; [@R28]).

To compare the gene expression profiles of differentiated GNPs and tumor cells, we purified differentiated (Tag1^+^) and proliferating (Tag1^−^) GNPs from wild-type cerebella at post-natal day 6 (P6), as well as differentiated (Tag1^+^) and Tag1^−^ tumor cells from *Ptch1*^+/−^ mice, and carried out RNA sequencing (RNA-seq) on each population. As revealed by PCA, although proliferating GNPs were well separated from Tag1^−^ MB cells, differentiated MB cells clustered close to differentiated GNPs, suggesting that differentiation of MB cells resembles that of GNPs ([Figure 3D](#F3){ref-type="fig"}). 1,721 genes differentially expressed between proliferating GNPs and differentiated GNPs, and expression of 1,615 genes was significantly altered between Tag1^−^ tumor cells and differentiated MB cells (log2 fold change \> 1.5 and p \< 0.05) ([Figure 3E](#F3){ref-type="fig"}). Among these differentially expressed genes, 975 genes were found associated with the differentiation of both GNPs and MB cells. Gene Ontology analysis revealed that these genes were enriched in regulators of the cell cycle and organelle organization ([Figure 3F](#F3){ref-type="fig"}), which is consistent with the cessation of proliferation and process extension during the differentiation of GNPs and MB cells. As shown in [Figure 3G](#F3){ref-type="fig"}, genes associated with neuronal maturation and process extension, including *Mapt*, *L1cam*, and *Stmn2*, were significantly elevated in both differentiated GNPs and MB cells, compared with dividing GNPs and Tag1^−^ MB cells, respectively. Expression of genes associated with the cell cycle, such as *Cenf* and *Ccna2*, was markedly downregulated in differentiated MB cells and GNPs ([Figure 3H](#F3){ref-type="fig"}). Notably, expression of Hh pathway target genes such as *Gli1* and *Ptch2* was decreased in both differentiated GNPs and MB cells compared with their dividing counterparts ([Figure 3I](#F3){ref-type="fig"}), suggesting that Hh signaling is repressed as both GNPs and MB cells undergo differentiation. Collectively, these data suggest that MB cells differentiate in a similar manner as GNPs.

Differentiation Overrides Hh Pathway Activation {#S6}
-----------------------------------------------

Consistent with our RNA-seq data, qPCR also revealed that expression of *Gli1* and *Gli2* was significantly decreased in differentiated tumor cells (Tag1^+^) compared with Tag1^−^ tumor cells (Tag1^−^) ([Figure 4A](#F4){ref-type="fig"}), further confirming the repression of Hh signaling in differentiated tumor cells. It was previously reported that the remaining wild-type allele of the *Ptch1* gene was lost in MB cells from *Ptch1*^+/−^ mice ([@R41]; [@R54]). Therefore, we examined the presence of the *Ptch1* gene in the genomic DNAs extracted from GNPs and MB cells by PCR. As expected, compared with wild-type GNPs, GNPs from *Ptch1*^+/−^ mice at P6 yielded approximately half the amount of PCR product of the *Ptch1* gene ([Figure 4B](#F4){ref-type="fig"}). However, almost no PCR product for the *Ptch1* gene was detected in differentiated MB cells (Tag1^+^) or Tag1^−^ tumor cells ([Figure 4B](#F4){ref-type="fig"}), suggesting that neither the differentiation capacity nor the reduction in Hh signaling of MB cells resulted from retention of the remaining wild-type allele of *Ptch1*. These findings indicate that Hh signaling was suppressed in differentiated tumor cells despite *Ptch1* deficiency.

To further investigate the effects of differentiation on Hh signaling, we purified Tag1^−^ tumor cells from *Ptch1*^+/−^ mice by FACS and plated them *in vitro* for 72 h. The majority of freshly isolated Tag1^−^ cells (0 h) were dividing and exhibited no markers of differentiation (βIII-tubulin) ([Figures 4C](#F4){ref-type="fig"}--[4E](#F4){ref-type="fig"}). However, after 72 h of culture, when almost no proliferation was detected, the MB cells expressed high levels of βIII-tubulin, indicating that they had spontaneously undergo differentiation *in vitro* ([Figures 4D](#F4){ref-type="fig"} and [4E](#F4){ref-type="fig"}). Expression of *Gli1* and *Gli2* was significantly downregulated in tumor cells as they differentiated *in vitro* ([Figure 4F](#F4){ref-type="fig"}). Infection with a lentivirus carrying *SmoM1* (a constitutively active form of Smo; [@R37]) or *Gli1* (two effectors downstream of Ptch1 in Hh pathway transduction), effectively activated the Hh pathway in GNPs, as evidenced by significant upregulation of *Ptch2*, a target gene of the Hh pathway ([Figure 4G](#F4){ref-type="fig"}). However, forced expression of *SmoM1* or *Gli1* failed to activate the Hh pathway in MB cells after being cultured for 72 h ([Figure 4H](#F4){ref-type="fig"}), suggesting that the Hh pathway cannot be activated in differentiated tumor cells. Collectively, the above data suggest that differentiation overrides Hh signaling in MB cells.

Enhanced Expression of NeuroD1 Induces MB Cell Differentiation {#S7}
--------------------------------------------------------------

Our data from scRNA-seq of MB cells revealed that expression of *NeuroD1*, a helix-loop-helix (HLH) transcription factor, was significantly upregulated in differentiated tumor cells compared with other cell populations in MB tissue ([Figure 5A](#F5){ref-type="fig"}). Enhanced expression of *NeuroD1* mRNA and protein was found in differentiated tumor cells (Tag1^+^) compared with Tag1^−^ tumor cells purified from mouse MB ([Figures 5B](#F5){ref-type="fig"} and [5C](#F5){ref-type="fig"}). To examine NeuroD1 expression in tumor tissue and its relationship to proliferation, we performed immunohistochemical staining for NeuroD1 on MB tissue from EdU-pulsed *Ptch1*^+/−^ mice. Approximately 20% of tumor cells were found to express NeuroD1 protein in mouse MB ([Figure 5D](#F5){ref-type="fig"}). Moreover, the majority of NeuroD1-positive tumor cells were not dividing (negative for EdU) ([Figure 5E](#F5){ref-type="fig"}) but instead co-expressed MAP2, a well-established marker for neuronal differentiation ([Figure 5F](#F5){ref-type="fig"}). These data suggest that MB cells increased NeuroD1 expression as they undergo differentiation. It was previously reported that NeuroD1 expression is required for normal differentiation of GNPs ([@R36]; [@R43]). Elevated expression of NeuroD1 proteins was also observed in differentiated GNPs in the dEGL as well as the IGL compared with dividing GNPs in the sEGL ([Figures S1G](#SD1){ref-type="supplementary-material"}--[S1H](#SD1){ref-type="supplementary-material"}). In addition, we examined the association of NeuroD1 expression and tumor cell proliferation in human MB by immunohistochemistry using a tissue microarray (TMA) containing 56 human MB sections. Elevated NeuroD1 expression was inversely associated with proliferation (based on the percentage of Ki67^+^ cells) in human MB ([Figures S2A](#SD1){ref-type="supplementary-material"}--[S2E](#SD1){ref-type="supplementary-material"}) (p \< 0.01, r = −0.79). Collectively, these data suggest that NeuroD1 induction is associated with differentiation of tumor cells in both mouse and human MB.

To examine whether *NeuroD1* can drive tumor cell differentiation, we infected MB cells with a lentivirus encoding *NeuroD1* along with a GFP tag or an empty GFP-encoding vector as a control. MB cells were pulsed with BrdU for 2 h before being harvested for immunocytochemistry. At 48 h post-infection, the majority of tumor cells infected with the control virus were positive for BrdU ([Figure 5G](#F5){ref-type="fig"}), whereas \<20% of NeuroD1-infected tumor cells were BrdU^+^ ([Figure 5H](#F5){ref-type="fig"}). No significant difference in the apoptosis was observed between NeuroD1-infected MB cells and cells infected with the control virus (data not shown). Ectopic expression of NeuroD1 induced tumor cell differentiation, as evidenced by a greater proportion of MB cells expressing MAP2, compared with GFP control ([Figures 5I](#F5){ref-type="fig"}--[5K](#F5){ref-type="fig"}). In addition to MAP2, NeuroD1 also stimulated the expression of other genes associated with neuronal differentiation, including *Mapt*, *L1cam*, and *NeuroD2* ([Figure S3A](#SD1){ref-type="supplementary-material"}). These data suggest that forced expression of *NeuroD1* repressed tumor cell proliferation and promoted differentiation. Consistent with our finding that differentiation can override Hh signaling in MB cells, the expression of Hh pathway target genes, including *Gli1* and *Ptch2*, was dramatically repressed in tumor cells after *NeuroD1* overexpression compared with control cells expressing GFP alone ([Figure S3B](#SD1){ref-type="supplementary-material"}).

Since cell differentiation is always accompanied by the downregulation of Hh signaling in primary MB cells or GNPs, we decided to utilize NIH 3T3 cells to investigate whether *NeuroD1* directly interferes with Hh signaling transduction independent of differentiation induction. For this purpose, we examined Hh signal transduction in NIH 3T3 cells after overexpressing *NeuroD1* or GFP as a control. No alterations in Hh signaling were observed in NIH 3T3 cells after forced expression of *NeuroD1* or GFP ([Figures S3C](#SD1){ref-type="supplementary-material"} and [S3D](#SD1){ref-type="supplementary-material"}), indicating that NeuroD1 is insufficient to directly repress Hh signal transduction but is capable of doing so indirectly in MB cells by inducing their differentiation. To examine whether NeuroD1 stimulated differentiation could affect tumorigenesis, we infected MB cells from *Ptch1*^+/−^ mice with a lentivirus encoding NeuroD1-GFP or GFP alone. Infected cells were purified by FACS and transplanted intracranially into *CB17/SCID* mice. As shown in [Figure 5L](#F5){ref-type="fig"}, *NeuroD1* overexpression completely prevented tumor formation in *CB17/SCID* mice (n = 18), while tumor cells infected with the control vector finally developed into tumors with 100% penetrance (n = 16; median survival, 47 days). These data further confirm that NeuroD1-induced differentiation abolishes the tumorigenicity of MB cells.

We further tested the differentiation-promoting effect of *NeuroD1* in human Hh MB cells (ICb-5610MB). Similar to our findings in mouse MB cells, NeuroD1 overexpression significantly decreased the percentage of BrdU^+^ cells and increased the number of βIII-tubulin^+^ cells among MB cells compared with GFP control ([Figures 5M](#F5){ref-type="fig"}--[5Q](#F5){ref-type="fig"}). These data confirm that NeuroD1 can promote the differentiation of both mouse and human MB cells. We next examined the alterations in tumorigenesis of human MB cells after forced expression of *NeuroD1* or GFP as a control by intracranial transplantation. The tumor incidence from NeuroD1-overexpressing MB cells (n = 6) was significantly repressed compared with that from control tumor cells (infected with GFP alone, n = 6; median survival, 34 days) ([Figure 5R](#F5){ref-type="fig"}). These data demonstrate that the tumorigenicity of MB cells was markedly compromised after overexpression of NeuroD1.

NeuroD1 Expression in MB Cells Is Regulated by EZH2-Mediated H3K27me3 {#S8}
---------------------------------------------------------------------

Previous studies reported that *NeuroD1* expression in tumor cells, including MB cells, may be regulated by DNA methylation ([@R12]; [@R22]). However, no difference in methylation of the *NeuroD1* gene was observed between differentiated tumor cells (Tag1^+^) and Tag1^−^ tumor cells isolated from *Ptch1*^+/−^ MB based on bisulfide sequencing analyses ([Figures S4A](#SD1){ref-type="supplementary-material"}--[S4E](#SD1){ref-type="supplementary-material"}). To investigate other possible epigenetic mechanisms regulating NeuroD1 expression in MB cells, we decided to perform a drug-screening assay to identify epigenetic compounds that can regulate NeuroD1 expression in MB cells. MB cells express basal levels of NeuroD1 even before their differentiation; thus, NeuroD1 expression is not a sensitive marker for drug screening. Having observed that increased NeuroD1 expression can repress MB cell proliferation and induce differentiation, we examined tumor cell proliferation and differentiation after treatment with agents targeting epigenetic regulators.

For this screen, we used a compound library consisting of 244 inhibitors against a variety of epigenetic regulators, including histone deacetylases (HDACs), histone demethylases, and histone acetyltransferases etc. ([Figure 6A](#F6){ref-type="fig"}). Tag1^−^ tumor cells purified from *Ptch1*^+/−^ mice by FACs were treated with individual compounds at 1 μM for 48 h. Before being collected for immunocyto-chemistry, tumor cells were pulsed with BrdU for 2 h. Compounds were classified as "proliferation repressing" if the percentage of BrdU^+^ cells in the culture was less than half of that in the control treatment (DMSO) ([Figure 6B](#F6){ref-type="fig"}). Tumor cell differentiation was also examined by immunostaining for p27/Kip1, a nuclear cyclin-dependent kinase inhibitor associated with neuronal differentiation ([@R38]; [@R52]). Compounds were defined as "differentiation promoting" if the percentage of p27/Kip1 was 1.5-fold more than that in the control ([Figure 6B](#F6){ref-type="fig"}). Of the 244 compounds, 51 compounds were found to be proliferation repressing, including 12 compounds that were observed as differentiation promoting. 39 compounds that only inhibited tumor cell proliferation but failed to induce tumor cell differentiation appeared to be cytotoxic. Among the 12 compounds exhibiting the capacity to both repress proliferation and stimulate differentiation of tumor cells were three EZH2 inhibitors (EPZ6438, UNC1999, and GSK126) ([Figures 6C](#F6){ref-type="fig"}--[6K](#F6){ref-type="fig"}). As shown in [Figure 6C](#F6){ref-type="fig"}--[6G](#F6){ref-type="fig"}, treatment with EPZ6438, UNC1999, or GSK126 significantly decreased the percentage of BrdU^+^ cells among MB cells compared with the vehicle control. Conversely, the percentage of p27/Kip1^+^ cells in MB cells was enhanced by treatment with EPZ6438, UNC1999, or GSK126 ([Figures 6H](#F6){ref-type="fig"}--[6L](#F6){ref-type="fig"}). Repressed cell proliferation and increased cell differentiation by treatment with EPZ6438, UNC1999, or GSK126 were also observed in human MB cells ([Figures S5A](#SD1){ref-type="supplementary-material"}--[S5J](#SD1){ref-type="supplementary-material"}). These data suggest that EZH2 inhibitors can suppress MB cell proliferation and stimulate tumor cell differentiation. We next examined NeuroD1 expression in tumor cells after the treatment with EZH2 inhibitors. As shown in [Figure 6M](#F6){ref-type="fig"}, expression of NeuroD1 protein in tumor cells was dramatically enhanced after treatment with EPZ6438, UNC1999, or GSK126 compared with control treatment. These findings imply that EZH2 may be involved in repressing NeuroD1 expression in MB cells.

To determine the possible role of EZH2 in regulating NeuroD1 expression in MB cells, we examined EZH2 protein in purified differentiated tumor cells (Tag1^+^) and Tag1^−^ tumor cells by western blotting. Expression levels of EZH2 protein were significantly elevated in Tag1^−^ tumor cells compared those in differentiated tumor cells ([Figure 6N](#F6){ref-type="fig"}). EZH2 is a catalytic subunit of the poly-comb repressive complex 2 (PRC2) that is involved in repressing gene expression through trimethylation of histone H3 on lysine 27 (H3K27). Having observed that EZH2 inhibitors increased NeuroD1 expression in MB cells, we next sought to examine whether NeuroD1 expression in MB cells was repressed by EZH2-mediated H3K27me3. Immunohistochemistry revealed that more than 70% of MB cells in *Ptch1*^+/−^ mice were positive for H3K27me3 ([Figure 6O](#F6){ref-type="fig"}). Moreover, majority of NeuroD1-expressing cells were found to be negative for H3K27me3 or EZH2 in MB tissue ([Figure 6P](#F6){ref-type="fig"} and [6Q](#F6){ref-type="fig"}), consistent with the notion that NeuroD1 expression in MB cells could be silenced by H3K27me3. To test this directly, we performed chromatin immunoprecipitation (ChIP) qPCR analysis for H3K27me3 marked chromatin to determine if the NeuroD1 promoter and enhancer were modified with H3K27me3 in differentiated and Tag1^−^ tumor cells purified from *Ptch1*^+/−^ MB ([Figure 6R](#F6){ref-type="fig"}) ([@R1]; [@R11]). H3K27me3 levels at all NeuroD1 promoter and enhancer regions were significantly reduced in differentiated MB cells compared with Tag1^−^ tumor cells ([Figure 6S](#F6){ref-type="fig"}). These data link the changes in NeuroD1 expression that drive MB differentiation to declined EZH2 expression and reduced occupancy of H3K27me3 on the *NeuroD1* loci.

We next infected MB cells with a lentivirus carrying short hairpin RNA (shRNA) specific for EZH2 (\#1 and \#2) or scrambled shRNA as a control. 48 h following the infection, EZH2 protein levels had declined significantly in tumor cells infected with shRNA specific for *EZH2*, as expected ([Figure 6T](#F6){ref-type="fig"}). The levels of NeuroD1 were elevated in EZH2-deficient tumor cells compared with control tumor cells with scrambled shRNA. EdU incorporation assay revealed that the proliferation was dramatically repressed in MB cells after EZH2 knockdown ([Figure 6U](#F6){ref-type="fig"}). In addition, we overexpressed EZH2 in MB cells by infection with a lentivirus encoding EZH2 or GFP alone as a control. The enhanced levels of EZH2 protein were confirmed in MB cells after forced expression of EZH2 ([Figure 6V](#F6){ref-type="fig"}). NeuroD1 expression was obviously repressed in MB cells with EZH2 overexpression compared to the control tumor cells with GFP alone ([Figure 6V](#F6){ref-type="fig"}). The proliferation of MB cells was increased after forced expression of EZH2, based on the EdU incorporation assay ([Figure 6W](#F6){ref-type="fig"}). These data further demonstrate that NeuroD1 expression was suppressed in MB cells by EZH2-mediated H3K27me3.

Histone acetylation is often associated with transcriptional activation ([@R5]; [@R9]). Interestingly, ChIP qPCR revealed increased occupancy of H3K27ac on loci of NeuroD1 promoter and enhancer regions in differentiated MB cells ([Figure S6A](#SD1){ref-type="supplementary-material"}). Consistent with this, elevated levels of H3K27ac were observed in differentiated MB cells, which were correlated with increased expression of NeuroD1 ([Figure S6B](#SD1){ref-type="supplementary-material"}). These data imply that H3K27ac may be involved in the induction of NeuroD1 expression during MB cell differentiation.

EZH2 Inhibitors Repress MB Growth by Promoting Tumor Cell Differentiation {#S9}
-------------------------------------------------------------------------

Having observed that tumor cell differentiation was driven by NeuroD1 and that NeuroD1 expression in MB cells is repressed by EZH2, we next examined the efficacy of EZH2 inhibitors (UNC1999, EPZ6438, and GSK126) for MB treatment.

MB cells isolated from *Ptch1*^+/−^ mice were treated with UNC1999, EPZ6438, or GSK126 at various concentrations for 48 h. As shown in [Figures 7A](#F7){ref-type="fig"}--[7C](#F7){ref-type="fig"}, all three compounds repressed cell proliferation in a dose-dependent manner. The IC~50~s (concentrations required to inhibit tumor cell viability by 50%) of UNC1999, GSK126, and EPZ6438 in repressing proliferation of *Ptch1*-deficient MB cells were 2.08 μM, 4.64 μM, and 8.74 μM, respectively.

To test whether inhibition of EZH2 can repress the proliferation of drug-resistant MB cells, we infected cerebellar GNPs with a lentivirus encoding SmoA1 (W539L), a constitutively activated form of Smo that renders the resistance of MB cells to vismodegib, an FDA-approved inhibitor of Hh pathway ([@R50]; [@R64]; [@R66]). 48 h following the infection, cells were treated with vismodegib, EZH2 inhibitors, or DMSO as a control. As expected, vismodegib failed to inhibit the proliferation of SmoA1-expressing GNPs ([Figures 7D](#F7){ref-type="fig"} and [7E](#F7){ref-type="fig"}). However, UNC1999, GSK126, or EPZ6438 significantly repressed the proliferation of SmoA1-expressing cells. These data suggest that EZH2 inhibitors can suppress the proliferation of drug-resistant MB cells.

It was previously reported that EZH2 inhibitors, including UNC1999, GSK126, and EPZ6438, could not efficiently penetrate the blood-brain barrier ([@R69]). Therefore, to test the effects of these compounds on tumor growth *in vivo*, we then generated subcutaneous MB models by injecting tumor cells from *Ptch1*^+/−^ mice into the flank of *CB17/SCID* mice ([@R20]; [@R27]). After tumors were established, tumor-bearing mice were treated with UNC1999 or GSK126 at dosages of 50 mg/kg and 100 mg/kg or vehicle control (methylcellulose) once a day by oral gavage. As shown in [Figure 7F](#F7){ref-type="fig"}, steady tumor growth was observed in the control group, with tumor volume reaching 2,000 mm^3^ by 10 days after the treatment. Compared with the control, GSK126 and UNC1999 significantly repressed tumor growth ([Figure 7G](#F7){ref-type="fig"}). Both drugs exhibited obvious dose-dependent efficacies in reducing MB growth, indicating that EZH2 inhibitors can suppress the growth of MB cells *in vivo*. To further investigate the basis for EZH2-inhibitor-repressed MB growth, subcutaneous tumors after drug treatment were harvested for immunohistochemistry. No significant weight loss was observed in mice treated with EZH2 inhibitors compared with control (data not shown). As shown in [Figures 7G](#F7){ref-type="fig"} and [7H](#F7){ref-type="fig"}, the majority of tumor cells in the control group were proliferative (Ki67^+^), whereas proliferation of tumor cells was significantly decreased after treatment with either UNC1999 or GSK126. A marked increase in differentiation (NeuN expression) was also observed in tumor tissue after treatment with EZH2 inhibitors, compared with only a few NeuN^+^ cells present in control tumors ([Figures 7G](#F7){ref-type="fig"} and [7I](#F7){ref-type="fig"}). In addition, enhanced apoptosis was found in tumor tissue upon the treatment with EZH2 inhibitors ([Figures 7G](#F7){ref-type="fig"} and [7J](#F7){ref-type="fig"}). Treatment with UNC1999 or GSK126 significantly induced NeuroD1 expression in tumor tissues compared with the control ([Figure 7K](#F7){ref-type="fig"}). These data suggest that EZH2 inhibitors effectively suppress MB growth by promoting tumor cell differentiation and repressing tumor cell proliferation.

To test the effects of EZH2 inhibitor on the growth of endogenous MB, we treated MB from *Ptch1*^+/−^ mice with EPZ6438. To facilitate blood-brain barrier penetration of EPZ6438, we pre-treated tumor-bearing mice with elacridar at 4 h prior to oral treatment with EPZ6438 or vehicle control ([Figure S7A](#SD1){ref-type="supplementary-material"}), as previously described ([@R25]). After treatment for 15 days, MB tissues were collected to examine tumor cell proliferation and differentiation by immunohistochemistry. Compared with the control, EPZ6438 treatment significantly repressed tumor cell proliferation ([Figures S7B](#SD1){ref-type="supplementary-material"} and [S7C](#SD1){ref-type="supplementary-material"}) and dramatically induced tumor cell differentiation ([Figures S7B](#SD1){ref-type="supplementary-material"}--[S7D](#SD1){ref-type="supplementary-material"}). NeuroD1 expression was markedly elevated in tumor tissues following the treatment with EPZ6438 ([Figure S7E](#SD1){ref-type="supplementary-material"}). These data further confirm that inhibition of EZH2 enhanced NeuroD1 expression in MB cells and promoted tumor cell differentiation. Finally, a MB mouse model was generated by intracranially injection of human Hh MB cells into *CB17/SCID* mice (ICb-5610MB). After MB was established, tumor-bearing mice were treated with EPZ6438 or vehicle control as described above. After treatment for 15 days, EPZ6438 markedly inhibited tumor cell proliferation ([Figures S7F](#SD1){ref-type="supplementary-material"} and [S7G](#SD1){ref-type="supplementary-material"}) and stimulated MB differentiation ([Figures S7F](#SD1){ref-type="supplementary-material"}--[S7H](#SD1){ref-type="supplementary-material"}). These data confirm the efficacy of EZH2 inhibitors in suppressing the growth of Hh-group MB.

DISCUSSION {#S10}
==========

It is widely accepted that tumor cells are characterized with unlimited replication as well as perturbed differentiation. These features of tumor cells stand in marked contrast to normal stem/progenitor cells, which can only divide a limited number of times before undergoing differentiation ([@R21]). Here, we demonstrate that MB cells maintain the capacity to differentiate in a manner similar to GNPs, the cells from which they originate. A rare population of cancer stem cells (Sox2^+^) was previously found to differentiate into mature granule neurons in MB tissue ([@R58]). Differentiated tumor cells irreversibly exit the cell cycle, lose their tumorigenic potential, and express genes associated with neuronal differentiation and maturation. In our studies, tumor cells proceed to differentiate despite oncogenic mutations such as *Ptch1* deficiency. These findings are consistent with the hypothesis of Pierce and colleagues that cell differentiation can override oncogenic mutations/transformation ([@R45]; [@R46]). During normal development, the Hh pathway is activated in GNPs in response to Shh secreted by Purkinje neurons ([@R6]; [@R62]). However, Hh signaling is repressed in GNPs when they initiate differentiation. Since GNPs migrate toward Purkinje neurons as they start to differentiate, it still remains unclear how Hh signaling is inactivated in GNPs in such a Shh-rich environment. Our finding that differentiation can override Hh signaling in MB cells suggests that differentiation intrinsically suppresses Hh signaling in GNPs.

Numerous studies have reported that MB cells resemble cerebellar GNPs in their morphology and expression of characteristic markers ([@R47]; [@R51]; [@R67]). Several recent studies elegantly demonstrated that human MB derives from disturbed development of cerebellum by single-cell transcriptomics ([@R23]; [@R59]). Here, we further reveal that MB cells resemble GNPs in their capacity for differentiation. These results implicate that tumor cells can be "normalized" into nonmalignant cells. Our findings are consistent with previous discoveries of Mintz and colleagues, who reported that after being injected into very early mouse embryos, teratoma cells participated in the normal development of the recipient mouse instead of forming malignancies ([@R35]). The normalization capacity of tumor cells argues that oncogenic transformation is a reversible process. In our studies, the bulk population of MB cells (Tag1^−^) consists of proliferating tumor cells, and a significant proportion of cells appear to be quiescent based on the scRNA-seq data. Future studies are warranted to further investigate the role of those quiescent cells in the initiation and progression of MB.

NeuroD1, a type E HLH transcription factor, was previously found to be necessary for differentiation of normal GNPs ([@R16]; [@R36]). Deletion of NeuroD1 disrupted GNP differentiation by prolonging the proliferation and induction of apoptosis in developing cerebella ([@R36]; [@R43]). Here, we found that NeuroD1 mRNA expression was markedly increased in differentiated tumor cells compared with bulk tumor cells in MB and forced expression of NeuroD1 promoted tumor cells differentiation. These data demonstrate that NeuroD1 drives tumor cell differentiation in MB. Basal levels of NeuroD1 expression were not absent in bulk tumor cells in MB. Knockdown of NeuroD1 expression in MB cells by shRNA caused extensive cell death (data not shown), in agreement with neuronal death observed in NeuroD1-null mice ([@R16]). It was recently reported that NeuroD1 acts as a key transcriptional mediator for group 3 MB ([@R2]). These findings indicate that NeuroD1 may have other functions besides differentiation induction during MB initiation and progression.

A previous study reported that bone morphogenic proteins (BMPs) can induce the differentiation of both GNPs and MB cells through post-transcriptional downregulation of Atoh1([@R70]). Consistent with our studies, MB growth was inhibited following the differentiation of tumor cells after BMP treatment. However, the levels of NeuroD1 as well as Zic1 and Pax6 proteins were either unchanged or even slightly decreased in GNPs *in vitro* upon BMP treatment, although these proteins are well-established markers for normal differentiation of GNPs ([@R30]). Future studies are warranted to examine whether similar changes in the protein levels of Zic1, Pax6, and NeuroD1 can be found in MB cells after BMP treatment.

It was previously reported that NeuroD1 expression in many malignancies, such as breast cancer and MB, can be regulated by DNA methylation ([@R12]; [@R22]). However, no difference in DNA methylation of NeuroD1 gene was observed between differentiated tumor cells and bulk tumor cells in MB cells from *Ptch1*^+/−^ mice. These data indicate that upregulation of NeuroD1 expression in differentiated MB cells may not be due to DNA methylation. By screening epigenetic compounds, we found that EZH2 inhibitors induced MB cell differentiation and enhanced NeuroD1 expression in MB cells. The expression of EZH2 mRNA and protein was significantly declined in differentiated MB cells. These data, together with our ChIP-PCR analysis, demonstrate that NeuroD1 expression in bulk tumor cells is repressed by EZH2-mediated H3K27me3. The increased occupancy of H3K27ac on NeuroD1 enhancer loci in differentiated MB cells suggests that NeuroD1 expression may be induced by H3K27ac during MB differentiation. Indeed, forced expression of EZH2 inhibited NeuroD1 expression in MB cells, whereas NeuroD1 expression was upregulated in MB cells following the EZH2 knockdown. These findings shed light on the molecular basis of NeuroD1 expression in MB cells, highlighting the important role of epigenetic regulations during MB progression.

In our studies, EZH2 inhibitors upregulated NeuroD1 expression in Hh-MB cells, and repressed the *in vivo* growth of Hh-MB. Interestingly, it was recently reported that *EZH2* inactivation promoted the progression of group 3 MB by upregulation of *Gfi1* ([@R60]). These findings suggest that EZH2 may exert distinct functions in different MB subgroups.

Traditional radiotherapy and chemotherapy act by damaging or killing tumor cells. However, these therapies often cause side effects that severely affect quality of life. Almost all MB patients suffer long-term adverse effects from these cytotoxic drugs, such as cognitive deficits and endocrine disorders ([@R55]; [@R57]). Differentiation therapy represents a more targeted and less toxic approach to tumor treatment ([@R7]; [@R8]; [@R15]; [@R34]). The underlying premise of differentiation therapy is that tumor cells can be reprogrammed to differentiate, thereby inhibiting tumor progression ([@R29]). As a standard therapeutic strategy for acute promyelocytic leukemia, all-trans-retinoic acid induces the cancer cells to differentiate from a granulocyte precursor into a mature myelocyte that can no longer divide ([@R4]; [@R61]). Here, we demonstrate that EZH2 inhibitors can induce NeuroD1 expression in *Ptch1*-deficient MB cells and promote their differentiation, thereby inhibiting tumor cell proliferation. More importantly, EZH2 inhibitors, including UNC1999, GSK126, and EPZ6438, significantly suppress the proliferation of SmoA1-expressing GNPs that are resistant to vismodegib, indicating that inhibition of EZH2 could be applied to treat drug-resistant MB cells. In our studies, EZH2 inhibitors exhibited promising efficiency in inducing tumor cell differentiation and suppressing the growth of human and mouse MB cells *in vivo*. Elevated levels of apoptosis were observed in MB tissues following treatment with EZH2 inhibitors, which are likely due to the ectopic differentiation among tumor cells *in vivo* as reported previously ([@R58]). EZH2 inhibitors induced significant differentiation in tumor cells *in vitro*, without inducing apoptosis. These data suggest that the repressed tumor growth after EZH2 treatment was predominately due to the enhanced differentiation of MB cells resulting from the upregulation of NeuroD1. As a repressive histone modification, H3K27me3 has been implicated in regulating the expression of many genes. It remains possible that other target genes of H3K27me3 are involved in the tumor-suppressing effects of EZH2 inhibitors.

Our studies provide rationales for utilizing EZH2 inhibitors in MB treatment. Clinical trials with EZH2 inhibitors are currently ongoing across a wide spectrum of malignancies, including pediatric lymphoma, prostate cancer, and solid tumors, and many have obtained a promising response in patients ([@R13]). To treating MB by targeting EZH2, future studies are needed to develop brain-penetrant EZH2 inhibitors or strategies to deliver these drugs to the CNS.

STAR★METHODS {#S11}
============

RESOURCE AVAILABILITY {#S12}
---------------------

### Lead Contact {#S13}

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Zeng-jie Yang (<Zengjie.Yang@fccc.edu>).

### Materials Availability {#S14}

No reagents were generated in this study.

### Data and Code Availability {#S15}

The single-cell RNA sequencing data generated in this study are available at NCBI Gene Expression Omnibus (accession number: GSE150752). The code used is available on request.

EXPERIMENTAL MODEL AND SUBJECT DETAILS {#S16}
--------------------------------------

### Mice {#S17}

*Ptch1*+/− mice, *Math1-Cre*ER^T2^ mice, *Math1-Cre* mice and *Rosa-GFP* mice were purchased from the Jackson Laboratory. *CB17/SCID* mice were bred in the Fox Chase Cancer Center Laboratory Animal Facility (LAF). All animals were maintained in the LAF at Fox Chase Cancer Center and all experiments were performed in accordance with procedures approved by the Fox Chase Cancer Center Animal Care and Use Committee. All mice were bred and genotyped as recommended by the Jackson Laboratory. For all mouse studies, mice of either sex were used. Ages of all mice used in experiments are indicated in the figure legends.

METHOD DETAILS {#S18}
--------------

### Cell culture and CCK8 assay {#S19}

For examining the *in vivo* efficacies, the stock solutions of UNC1999, GSK126 and EPZ6438 (in DMSO, 100mg/ml) were diluted using 0.5% methylcellulose plus 0.2% Tween-80 (MCT), which were administrated to mice by oral gavage. To facilitate the brain penetration of EPZ6438, Elacridar (100mg/kg) dissolved in DMSO/corn oil (1:9), was orally gavaged 4 hr prior to EPZ6438 treatment. Tamoxifen (Sigma-Aldrich, T5648) was dissolved at a concentration of 20 mg/ml in corn oil and administrated once by oral gavage at a dosage of 200 mg/kg. MB tissues were harvested at 1 week following the tamoxifen treatment.

GNPs and MB cells were isolated from wild-type mice at P7, and *Ptch1*+/− mice at 30 weeks of age, respectively. Cerebella or tumor tissue were digested in a papain solution to obtain a single-cell suspension and then centrifuged through a 35% and 65% Percoll gradient. Cells from the 35% to 65% interface were suspended in Dulbecco's PBS (DPBS) plus 0.5% BSA. Cells were then suspended in NB-B27 (Neurobasal with 1 mM sodium pyruvate, 2 mM L-glutamine, B27 supplement and 1% Pen/Strep, all from Invitrogen) and plated on poly-D-lysine (PDL)-coated coverslips (BD Biosciences). NIH 3T3 cells were cultured in DMEM with 10% fetal bovine serum, 1% Pen/Strep and 2mM L-glutamine (Invitrogen).

The cell survival was determined using Cell Counting Kit-8 (CCK-8) kit. MB cells were plated at a density of 2 × 10^5^ cells/well in 96-well multiplates. After drug treatment for 48 hr, 10 μL of CCK-8 solution was added to each well and further incubated for 2 hr. Then, the absorbance values were detected at a wavelength of 450 nm using a Bio-Rad microplate reader. The cell viability was calculated by the optical density (OD) values of treated groups/OD values of control groups × 100%. In some experiments, cells were pulsed with BrdU (10μM) for 2 hr before being harvested to examine cell proliferation by immunocytochemistry.

### Tumor transplantation {#S20}

MB cells were injected into the cerebella of *CB17/SCID* mice using a stereotaxic frame with a mouse adaptor (David Kopf Instruments), as described previously ([@R65]). Before transplantation, MB cells were infected with lentivirus carrying GFP-tagged NeuroD1 or empty GFP vector for 24hrs, and infected MB cells (GFP+) were then purified by FACS. For transplantation with MB cells (human or mouse) after the virus infection, the cell suspension was centrifuged at 900rpm for 5 mins to remove the supernatant (containing dead cells). 5×10^5^ viable cells (based on Trypan blue staining) were injected into the cerebellum of each mouse. Survival was defined as the time from transplantation until symptom onset.

*CB17/SCID* male mice of age 6--8 weeks were used for subcutaneous allograft establishment. Cells isolated from tumor-bearing mice in a single-cell suspension in PBS at concentration 2 × 10^6^ cells was mixed with reduced growth factor Matrigel (Corning) in a 20:80 ratio and injected subcutaneously on the flank of *CB17/SCID* mice. 4 weeks following injection, tumor-bearing mice that satisfied initial tumor volume requirement (200--400mm^3^) were randomized into experimental groups. Compounds were administrated once a day and tumor size measurements were taken every day and tumor volume calculated as described previously ([@R56]).

### Immunostaining, flow cytometry, western blotting and TMA analysis {#S21}

Immunofluorescent staining of sections and cells was carried out according to standard methods. Briefly, sections or cells were blocked and permeabilized for 1 hr with PBS containing 0.1% Triton X-100 and 10% normal goat serum, stained with primary antibodies overnight at 4°C, and incubated with secondary antibodies for 2 hr at room temperature. Sections or cells were counter-stained with DAPI and mounted with Fluoromount-G (Southern Biotech) before being visualized using a Nikon Eclipse Ti microscope. For purifying differentiated MB cells, tumor cells were incubated with the primary antibody against Tag1 (1:50, mouse IgM, DSHB) on ice for 30 mins. After washing with PBS for 3 times, tumor cells were incubated with Texas Red-conjugated secondary antibody for 30 mins. Tag1- tumor cells and differentiated tumor cells (Tag1+) were then fractionated by FACs. In some experiments, MB-bearing mice were treated with EdU (10mg/ml) by intraperitoneal injection, at 2hrs before sacrifice.

For western blot analysis, cells were lysed in RIPA buffer (Thermo) supplemented with protease and phosphatase inhibitors (Thermo). Total lysate containing equal amount of protein were separated by SDS-PAGE gel and subsequently transferred onto PVDF membrane. Membranes were then subjected to probe with antibodies. Western blot signals were detected by using Super-Signal West Pico Chemiluminescent substrate (Thermo) and exposed on films.

Totally human MB TMAs containing a total of 126 (duplicate) cores from 63 samples (including 56 MB samples and 7 control tissue samples) were used for analyzing the correlation between NeuroD1 expression and tumor cell proliferation. After immunostaining with antibodies against Ki67 or NeuroD1, the slides were independently viewed and scored by two experienced pathologists. H-score was generated for NeuroD1 expression on the slide. The H score consists of the product of the intensity of nuclearstaining (0--3+) and the percentage of cells with nuclear staining. The range of the H score was 0 to 300 (0% cells positive to 100% cells 3+positive). The correlation between H score of NeuroD1 expression and the percentage of Ki67+ cells, was analyzed by calculating the spearman rho correlation coefficient.

### Q-PCR, DNA methylation assay and ChIP-PCR {#S22}

RNA was isolated using the RNAqueous kit (Ambion) and treated with DNA-free DNase (Ambion). cDNA was synthesized using oligo(dT) and Superscript II reverse transcriptase (Invitrogen). Quantitative PCR reactions were performed in triplicate using iQ SYBR Green Supermix (Bio-Rad) and the Bio-Rad iQ5 Multicolor Real-Time PCR Detection System. Primer sequences are available upon request.

For DNA methylation assay, genomic DNA was subjected to the sodium bisulfite modification reaction as previously described. Products from the bisulfite reactions were amplified by PCR using primers designed with the MethPrimer software at <http://www.urogene.org/methprimer/>. Purified PCR products were subcloned into pGEM T-Easy vector (Invitrogen), and individual inserts from 10--15 clones were sequenced.

For ChIP-PCR, MB cells were fixed with 1% formaldehyde for 10minutes at room temperature, and then quenched by incubation with glycine for 10 minutes. Cells were lysed with 1 mL Lysis Buffer 1 (50mM HEPES-KOH, 140 mM NaCl, 1mM EDTA, 10% glyerol, 0.5% NP-40, 0.25% Triton X-100) at 4°C for 10 minutes. After spinning for 5 min at 700xg at 4°C, cells were washed with 1 mL Lysis Buffer 2 (10mM Tris-HCl, 200mM NaCl, 1mM EDTA, 0.5mM EGTA) at 4°C for 10 minutes. The nuclei were pipetted in 200 μL Lysis Buffer 3 (50mM Tris-HCl, 1%SDS, 10mM EDTA). After sonication, the cell lysate was centrifuged to collect the supernatant. Protein G Dynabeads (Life technologies) were used to binding antibody against H3K27me3 or H3K27ac, and immuno-precipitated with diluted chromatin at 4°C on rotating overnight. Rabbit IgG as a negative control. The chromatin/antibody-beads mixture was washed and eluted with 200ul Elution Buffer (10mM Tris-HCl, 0.5% SDS, 300mM NaCl, 5mM EDTA) to reverse crosslinks at 65°C overnight. The DNA were purified and extracted by ChIP DNA Clean and Concentrator Kit (Zymo) according to the manufacturer's protocol. ChIP-PCR was performed using the purified DNA as a template (ChIP 1:2, input 1:10), and quantified by SYBR Green PCR Kits (QIAGEN). To compare the enrichment of DNA pulled down by H3K27me3 or H3K27ac antibody at potential binding sites between Tag1+ and Tag1- populations, ChIP-qPCR data were normalized and relative to 2% of input DNA.

### Single-Cell RNA Sequencing and data analyses {#S23}

Viable single cells were loaded on to a 10X Genomics Chromium Controller instrument to generate single-cell barcoded droplets (GEMs) using the 10x Single Cell 3′ Gel Bead Kit and 10x Chromium system at GENEWIZ following as the manufacturer's protocol. Briefly, single cells were partitioned into Gel Beads in Emulsion (GEMs) in the Chromium Controller instrument with cell lysis and barcoded reverse transcription of RNA, followed by cDNA amplification, shearing, library construction and indexing by PCR amplification. Subsequently, libraries were sequenced by Illumina 2×150 bp sequencing.

The Cell Ranger Single Cell Software Suite v.2.0.1 (<https://support.10xgenomics.com/>) by 10x Genomics was used to perform sample de-multiplexing, barcode processing and single-cell 3′ gene counting. In brief, base call files were fastq format were aligned to the mm10 reference genome that used an aligner called STAR with default settings, and aligned reads were filtered for valid cell barcodes and UMI to generate filtered gene-barcode matrices. The pre-processed 10X and DGE matrices were then imported using the Seurat package for the R programming language (version 3.5.4), and the data were filtered to include genes detected in \> 5 cells, and cells with 500\~6000 detected genes and UMI with 1000\~30000 and \< 15% mitochondrial genes. For single-dataset analyses, Log-normalized expression values were obtained by the NormalizeData function, and variable genes were identified using the FindVariableGenes Seurat function, TPM values were obtained from raw UMI counts by normalizing with total UMI counts per cell. Next, Principle components analysis (PCA) was performed and significant PCs were used as input for graph-based clustering. 2-dimensional visualization of the multi-dimensional dataset was done with t-SNE. For clustering, we used the function FindClusters that implements SNN (shared nearest neighbor) modularity optimization based clustering algorithm on 15 PCA components with resolution 0.1--0.5, leading to 5--12 clusters. A resolution of 0.25 was chosen for the analysis.

Single cell gene expression profiling data from human MB (GSE119926) were obtained from the Gene Expression Omnibus (GEO) database (<https://www.ncbi.nlm.nih.gov/geo/>). After pretreatment of raw data and preparation of profile matrix, Seurat3 R package was used for further data analysis.

### Profiling differentially expressed genes within each cell cluster {#S24}

To identify differentially expressed genes in each cell cluster, we applied the FindAllMarkers function from Seurat to the normalized gene expression data. Here, we selected a power value greater than 0.25 as the cut-off for gene selection. The gene expression levels plotted by packages in R. For cell type analysis, we performed differentially expressed gene (DEG) analysis by comparing each cluster with the other clusters using the Wilcoxon rank sum test. Genes with scaled dispersion \> 0.25 and log-normalized average expression \> 0.01 were included in the analyses. For each cluster, DEGs with top 1.5 fold changes were designated as a cell type signature, Thresholds were set as P value \< 0.05. If a cell type signature gene overlapped among different clusters, the gene was assigned to the cluster having the highest expression value. To characterize clusters, we used known marker genes that was reported to compare the differentially expressed gene use GeneQuery and Enrichment analysis. For heatmap representation, normalized expression of markers inside each cluster was used.

### RNA sequencing {#S25}

Total RNA was extracted from purified GNPs and MB cells. Strand-specific mRNA-seq libraries for the Illumina platform were generated and sequenced at at GENEWIZ following the manufacturer's protocol. High-quality total RNA was used as input for the so-called dUTP library preparation method. Briefly, the mRNA fraction was purified from total RNA by polyA capture, fragmented and subjected to first-strand cDNA synthesis with random hexamers in the presence of Actinomycin D. The second-strand synthesis was performed incorporating dUTP instead of dTTP. Barcoded DNA adapters were ligated to both ends of the double-stranded cDNA and subjected to PCR amplification. The resultant library was checked on a Bioanalyzer (Agilent) and quantified. The libraries were multiplexed, clustered, and sequenced on an Illumina HiSeq 2000. The sequencing run was analyzed with the Illumina CASAVA pipeline (v1.8.2), with demultiplexing based on sample- specific barcodes. The raw sequencing data produced was processed removing the sequence reads which were of too low quality (only "passing filter" reads were selected) and discarding reads containing adaptor sequences or PhiX control with an in-house filtering protocol.

QUANTIFICATION AND STATISTICAL ANALYSIS {#S26}
---------------------------------------

Student's t test was performed to determine the statistical significance of the difference. p \< 0.05 was considered statistically significant (\*, p \< 0.05; \*\*, p \< 0.01; \*\*\*, p \< 0.001; \*\*\*\*, p \< 0.0001; ns, not significant). Error bars represent the SEM. Overall survival was assessed using the Kaplan-Meier survival analysis and the Mantel-Cox log-rank test was used to assess the significance of difference between survival curves. Data handling and statistical processing was performed using Microsoft Excel and Graphpad Prism Software.
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![Tumor Cell Differentiation in Ptch1-Deficient MB\
(A) tSNE plot showing cell clusters based on transcriptomes of cells isolated from MB in *Ptch1*^+/−^ mice. Cell clusters are color coded.\
(B) tSNE plots displaying the expression levels of *Zic1* and *Barhl1* in all cell clusters.\
(C) Heatmap of single-cell data based on the tSNE plot. Columns represent individual cells, and rows represent genes.\
(D) Dot plot showing the expression of marker genes in each cell clusters. The size of the dot reflects the percentage of cells expressing the gene. Expression levels are color coded.\
(E) The percentage of each clusters in total cells isolated from MB.\
(F and G) tSNE plots showing the expression of neuronal differentiation genes (F) and cell-cycle-associated genes (G) in all cell clusters.\
(H) tSNE plot showing tumor groups based on transcriptomes of human MB cells. Tumor groups are color coded.\
(I and J) tSNE plots showing the expression of neuronal differentiation genes (I) and cell-cycle-associated genes (J).\
A green line circles the differentiated cell cluster in (F), (G), (I), and (J).](nihms-1607415-f0002){#F1}

![Differentiated MB Cells Are Not Tumorigenic\
(A--C) MB tissues from *Ptch1*^+/−^ mice were harvested for H&E staining (A) and immunostaining for Tag1/Ki67 (B) and Tag1/MAP2 (C). Tumor regions shown in\
(B) and (C) correlate the box region in (A).Scale bars,75 μm (A) and 50 μm (B and C).\
(D) Histograms of tumor cells by flow cytometry after immunostaining with an antibody against Tag1 (top) or isotype control (bottom).\
(E and F) Tag1^−^ (E) or Tag1^+^ tumor cells (F) purified from *Ptch1*^+/−^ mice, were pulse labeled with BrdU for 2 h before immunocytochemistry (E and F). DAPI was used to counterstain cell nuclei. Scale bars, 25 μm.\
(G) Percentage of BrdU^+^ cells in Tag1^−^ and Tag1^+^ tumor cells.\
(H) Survival curves of *CB17/SCID* mice after intracranial transplantation of Tag1^−^ or Tag1^+^ MB cells (2 × 10^5^ cells/mouse) purified from *Ptch1*^+/−^ mice by FACs.\
(I) Whole-mount picture of a *Math1-CreER*^*T2*^*/Rosa-GFP/Ptch1*^+/−^ mice after tamoxifen treatment and injection with EdU at 2 h before sacrifice. Arrows point to the GFP-positive MB.\
(J--L) MB tissue sections from *Math1-CreER*^*T2*^*/R26-GFP/Ptch1*^+/−^ mice after tamoxifen treatment were triple immunostained for Tag1, EdU, and GFP. The same section shows the expression of Tag1/GFP (J), EdU/GFP (K), and Tag1/EdU (L). Insets in (J) and (K) show high-power views. Scale bars, 50 μm.](nihms-1607415-f0003){#F2}

![MB Cells Resemble GNPs in Their Differentiation\
(A) Schematic of GNP differentiation in developing cerebellum. After completing their initiation proliferation in cerebellar sEGL, GNPs migrate through the dEGL to their final destination, the IGL.\
(B and C) Cerebellar sections from wild-type cerebella at P6 were immunostained for Tag1/Ki67 (B) and βIII-tubulin/Ki67 (C). Insets show higher magnifications in (B) and (C). Arrows point to Tag1 expression (B) or βIII-tubulin expression (C). Scale bars, 100 μm.\
(D) PCA of Tag1^−^ tumor cells, differentiated tumor cells (Tag1^+^), dividing GNPs (Tag1^−^), and differentiated GNPs (Tag1^+^) based on their transcriptomes.\
(E) A Venn diagram showing the number of genes differentially expressed in dividing MB cells/GNPs and their differentiated counterparts.\
(F) Gene Ontology (GO) analysis of differentially expressed genes based on biological processes.\
(G--I) Heatmaps show the expression of genes associated with neuronal differentiation (G), cell cycle (H), and the Hh pathway (I) in tumor cells and GNPs.](nihms-1607415-f0004){#F3}

![Differentiation Overrides Hh Signaling in MB Cells\
(A) mRNA expressions of *Gli1* and *Gli2* in purified differentiated tumor cells (Tag1^+^) and Tag1^−^ tumor cells (Tag1^−^) by qPCR.\
(B) Relative abundance of *Ptch1* gene in GNPs and MB cells examined by conventional PCR.\
(C and D) Purified Tag1^−^ MB cells were harvested at 0 h (C) or 72 h (D) in culture to examine Ki67 and βIII-tubulin expressions by immunocytochemistry. DAPI was used to counterstain cell nuclei. Scale bars, 50 μm.\
(E) Percentage of Ki67^+^ and βIII-tubulin^+^ cells among MB cells at 0 and 72 h.\
(F) mRNA expression of *Gli1* and *Gli2* in cultured MB cells at 0 and 72 h.\
(G) mRNA expression of *Ptch2* in cerebellar GNPs infected with a lentivirus carrying GFP control, *SmoM1*, or *Gli1*.\
(H) mRNA expression of *Ptch2* in MB cells cultured for 72 h after overexpression of *SmoM1*, *Gli1*, or GFP control.](nihms-1607415-f0005){#F4}

![NeuroD1 Expression Stimulates MB Cell Differentiation\
(A) Based on the transcriptomics of MB cells from scRNA-seq, a dot plot showing expression levels of *NeuroD1* mRNA in cell clusters in MB tissue. Each dot represents an individual cell.\
(B and C) NeuroD1 protein (B) and mRNA (C) expression in Tag1^+^ and Tag1^−^ cells purified from MB tissue and examined by western blotting and qPCR, respectively.\
(D) NeuroD1 protein expression in paraffin-embed sections of mouse MB by immunohistochemistry. Scale bar, 50 μm.\
(E and F) NeuroD1/EdU (E) and NeuroD1/MAP2 (F) expression in MB sections examined by immunohistochemistry. Scale bars, 50 μm.\
(G--K) MB cells after overexpressing *NeuroD1* (H and J) or *GFP* alone (G and I), were examined for BrdU (G and H) and MAP2 (I and J) expressions by immunocytochemistry. Scale bars, 25 μm (G-J).\
(K) Percentage of BrdU^+^ cells as well as MAP2^+^ cells among infected MB cells (GFP^+^).\
(L) Survival curves of *CB17/SCID* mice after intracranial transplantation of MB cells with overexpression of *NeuroD1* or *GFP* alone.\
(M--R) Human Hh-group MB cells infected with lentivirus encoding *GFP* (M and O) or *NeuroD1* (N and P) were pulsed with BrdU for 2 h before being harvested to examine BrdU and βIII-tubulin by immunocytochemistry. (Q) Percentages of BrdU^+^ cells and βIII-tubulin^+^ cells among infected MB cells (GFP^+^). (R) Survival curves of *CB17/SCID* mice after intracranial injection of human MB cells with overexpression of *NeuroD1* (n = 6) or *GFP* alone (n = 6). Scale bars, 25 μm (M--P).](nihms-1607415-f0006){#F5}

![NeuroD1 Expression in MB Cells Was Repressed by H3K27me3\
(A) Epigenetic compounds used for drug screening. The numbers in parentheses indicate the number of compounds in each category.\
(B) Distribution of compounds in affecting tumor cell proliferation or differentiation.\
(C--L) MB cells treated with DMSO (control, C and H), GSK126 (D and I), UNC1999 (E and J), or EPZ6438 (F and K) (all at 1 μM) for 48 h were collected to examine BrdU (C--F) or P27 (H--K) by immunocytochemistry. The percentage of BrdU^+^ cells (G) or P27^+^ cells (L) in the culture was quantified. DAPI was used to counterstain cell nuclei. Scale bars, 50 μm (C-F and H--K).\
(M) NeuroD1 expression in MB cells after designated treatment, as examined by western blotting.\
(N) EZH2 protein expression in purified Tag1^+^ MB and Tag1^−^ MB cells, as examined by western blotting.\
(O) H3K27me3 protein expression in paraffin embedded MB tissue from *Ptch1*^+/−^ mice, as examined by immunohistochemistry. Scale bar, 50 μm.\
(P and Q) NeuroD1/H3K27me3 (P) and NeuroD1/EZH2 (Q) expression in frozen MB tissues from *Ptch1*^+/−^ mice by immunohistochemistry. Insets show high-power views. Scale bars, 50 μm.\
(R) A schematic showing locations of PCR primers used for detecting occupancy of H3K27me3 or H3K27ac on NeuroD1 promoter or enhancers.\
(S) Enrichment of H3K27me3 on NeuroD1 loci in purified Tag1^+^ and Tag1^−^ MB cells.\
(T--W) MB cells from *Ptch1*^+/−^ mice were infected with shRNAs specific for EZH2 (Sh-EZH2\#1 and Sh-EZH2\#2) or scrambled shRNA, as well as with EZH2 or GFP alone for 48 h, and pulsed labeled with EdU for 2 h before collection. EZH2 and NeuroD1 proteins in infected cells were examined by western blotting (T and V). GAPDH was used as a loading control. The percentage of EdU^+^ cells among infected cells is quantified (U and W).](nihms-1607415-f0007){#F6}

![EZH2 Inhibitors Effectively Repress MB Growth\
(A--C) IC~50~ values of UNC1999 (A), GSK126 (B), and EPZ6438 (C) in repressing MB proliferation, as examined by CCK8 assay.\
(D and E) GNPs from P6 wild-type cerebella were infected with lentivirus encoding SmoA1-GFP and treated with vismodegib (400 nM), UNC1999 (2 μM), GSK126 (2 μM), or EPZ6438 (2 μM) for 48 h. GNPs after the treatment were examined for proliferation (EdU^+^) by immunostaining (D). The percentage of EdU^+^ cells in infected GNPs after treatment is quantified (E). Scale bar, 50 μm (D).\
(F) Fold changes in the volume of subcutaneous MBs after the designated treatment, and the size of subcutaneous MB after drug treatment (right).\
(G--K) Subcutaneous MB tissue after treatment with vehicle, GSK126 (100 mg/kg), or UNC1999 (100 mg/kg) was immunostained for Ki67, NeuN, or cleaved caspase-3 by immunohistochemistry (G). DAPI was used to counterstain cell nuclei. The percentage of Ki67^+^ cells (H), NeuN^+^ cells (I), or CC3^+^ cells (J) is quantified. NeuroD1 protein expression in MB tissue after the treatment was examined by western blotting and quantified (K). GAPDH was used as a loading control. Scale bar, 50 μm (G).](nihms-1607415-f0008){#F7}

###### 

KEY RESOURCES TABLE

  REAGENT or RESOURCE                                                SOURCE                                    IDENTIFIER
  ------------------------------------------------------------------ ----------------------------------------- -------------------------------------
  Antibodies                                                                                                   
  Rabbit monoclonal anti-Ki67                                        Abcam                                     Cat\#ab15580; RRID: AB_443209
  Mouse monoclonal anti-NeuN                                         Abcam                                     Cat\#ab104224; RRID: AB_10711040
  Mouse monoclonal anti-beta III Tubulin                             Abcam                                     Cat\#ab78078; RRID: AB_2256751
  Rabbit monoclonal anti-Cleaved Caspase-3                           Cell Signaling Technology                 Cat\#9664; RRID: AB_2070042
  Rabbit monoclonal anti-Microtubule-Associated Protein 2 (MAP2)     Millipore                                 Cat\# AB5622; RRID: AB_91939
  Rabbit Polyclonal anti-MEF2D                                       Abcam                                     Cat\#ab32845; RRID:AB_776269
  Mouse monoclonal anti-Neurofilament (NF-M)                         DSHB                                      Cat\#2H3; RRID:AB_531793
  Mouse monoclonal anti-TAG-1                                        DSHB                                      Cat\#4D7/TAG1; RRID:AB_531775
  Rabbit monoclonal anti-ZIC1                                        Gift from Dr. Rosalind Segal              N/A
  Mouse monoclonal anti-Neurod1                                      Abcam                                     Cat\# ab60704; RRID: AB_943491
  Chicken Polyclonal anti-GFP                                        Thermo Fisher Scientific                  Cat\#A10262; RRID:AB_2534023
  Mouse monoclonal anti-BrdU                                         Sigma-Aldrich                             Cat\#B8434; RRID:AB_476811
  Rabbit Polyclonal anti-HA                                          Sigma-Aldrich                             Cat\#H6908; RRID:AB_260070
  Mouse monoclonal anti-p27                                          Santa Cruz Biotechnology                  Cat\#sc-1641; RRID:AB_628074
  Rabbit monoclonal anti-Histone H3, Trimethyl (Lys27)               Cell Signaling Technology                 Cat\#9733; RRID:AB_2616029
  Rabbit monoclonal anti-EZH2                                        Cell Signaling Technology                 Cat\#5246; RRID:AB_10694683
  Rabbit monoclonal anti-Acetyl-Histone H3 (Lys27)                   Cell Signaling Technology                 Cat\#8173; RRID:AB_10949503
  Rabbit monoclonal anti-GAPDH                                       Cell Signaling Technology                 Cat\#2118; RRID:AB_561053
  Biological Samples                                                                                           
  human MB PDX lines                                                 Northwestern University                   ICb-5610MB
  human MB TMAs                                                      The Children's Hospital of Philadelphia   Human MB collections
  Chemicals, Peptides, and Recombinant Proteins                                                                
  Tamoxifen                                                          Sigma-Aldrich                             CAS\#10540-29-1
  UNC1999                                                            CAYMAN                                    CAS\#1431612-23-5
  GSK126                                                             CAYMAN                                    CAS\#1346574-57-9
  EPZ-6438                                                           CAYMAN                                    CAS\#1403254-99-8
  Elacridar                                                          MedChemExpress                            CAS\#143664-11-3
  Epigenetics compound library                                       MedChemExpress                            CAS\#HY-L005
  Critical Commercial Assays                                                                                   
  Cell Counting Kit-8                                                MedChemExpress                            CAS\#HY-K0301
  EZ DNA Methylation-Gold Kit                                        Zymo Research                             CAS\#D5005
  ChIP DNA Clean & Concentrator                                      Zymo Research                             CAS\#D5205
  High-Capacity cDNA Reverse Transcription Kit                       Thermo Fisher                             CAS\#4368814
  SYBR Green PCR Master Mix                                          QIAGEN                                    CAS\#330501
  Deposited Data                                                                                               
  Single-cell RNaseq                                                 This paper                                Accession number:GSE150752
  Single-cell RNaseq                                                 [@R23]                                    Accession number:GSE119926
  Experimental Models: Organisms/Strains                                                                       
  Mouse: Tg(Atoh1-cre/Esr1\*)14Fsh/J (Also known as Math1-CreERT2)   Jackson Laboratory                        <https://www.jax.org/strain/007684>
  Mouse: Ptch1tm1Mps/J (Also known as Ptch+/−)                       Jackson Laboratory                        <https://www.jax.org/strain/003081>
  Mouse: Tg(Atoh1-cre)1Bfri (Also known as Math1-Cre)                Jackson Laboratory                        <https://www.jax.org/strain/011104>
  Mouse: B6;129-Gt(ROSA)26Sortm2Sho/J (Also known as Rosa-GFP)       Jackson Laboratory                        <https://www.jax.org/strain/004077>
  Mouse: CB17/SCID                                                   Fox Chase Cancer Center                   N/A
  Oligonucleotides                                                                                             
  QPCR-Gli1 F:5′CCAAGCCAACTTTATGTCAGGG3′                             Integrated DNA Technologies               N/A
  QPCR-Gli1R: 3′AGCCCGCTTCTTTGTTAATTTGA5′                            Integrated DNA Technologies               N/A
  QPCR-Gli2F: 5′GCCCTGGAGAGTCACCCTT3′                                Integrated DNA Technologies               N/A
  QPCR-Gli2R: 3′TGCACAGACCGGAGGTAGT5′                                Integrated DNA Technologies               N/A
  QPCR-Ptch2F: 5′GGCACTCACATCCGTCAACAAC3′                            Integrated DNA Technologies               N/A
  QPCR-Ptch2F: 3′GAAGACGAGCATTACCGCTGCA5′                            Integrated DNA Technologies               N/A
  QPCR-Neurod1 F: 5′CCTTGCTACTCCAAGACCCAGA3′                         Integrated DNA Technologies               N/A
  QPCR-Neurod1R: 3′TTGCAGAGCGTCTGTACGAAGG5′                          Integrated DNA Technologies               N/A
  QPCR-Neurod2F: 5′GCTACTCCAAGACGCAGAAGCT3′                          Integrated DNA Technologies               N/A
  QPCR-Neurod2R: 3′CACAGAGTCTGCACGTAGGACA5′                          Integrated DNA Technologies               N/A
  QPCR-MaptF: 5′CCTGAGCAAAGTGACCTCCAAG3′                             Integrated DNA Technologies               N/A
  QPCR-MaptR: 3′CAAGGAGCCAATCTTCGACTGG5′                             Integrated DNA Technologies               N/A
  QPCR-L1camF: 5′CTGCTGAAGACCACAACTCTCC3′                            Integrated DNA Technologies               N/A
  QPCR-L1camR: 3′CCGAAAGGTGTAGTGGACATAGG5′                           Integrated DNA Technologies               N/A
  ChIP-PCR-Neurod1\#1F: 5′TCACCCCTCCCCAGAACTTTCCT3′                  Integrated DNA Technologies               N/A
  ChIP-PCR-Neurod1\#1R: 3′AATAGGCAGGTCACGTGGTTCCC5′                  Integrated DNA Technologies               N/A
  ChIP-PCR-Neurod1\#2F: 5′ACAATGCTCCTTGCTTGCTC3′                     Integrated DNA Technologies               N/A
  ChIP-PCR-Neurod1\#2R: 3′GCATTGTGGGAGTTCTTTGG5′                     Integrated DNA Technologies               N/A
  ChIP-PCR-Neurod1\#3F: 5′GTCTTGTCAGAACCTTGCCTTC3′                   Integrated DNA Technologies               N/A
  ChIP-PCR-Neurod1\#3R: 3′CCCAGCATAGTTCTTGGATACC5′                   Integrated DNA Technologies               N/A
  ChIP-PCR-Neurod1\#4F: 5′TGAACAGGGAGAGAGGCAAG3′                     Integrated DNA Technologies               N/A
  ChIP-PCR-Neurod1\#4R: 3′CCATTTTGCAGTGGACTCCT5′                     Integrated DNA Technologies               N/A

###### Highlights

-   Medulloblastoma cell differentiation can resemble that of cerebellar neuronal progenitors

-   Differentiated tumor cells permanently lose their tumorigenic capacity

-   NeuroD1 drives the differentiation of medulloblastoma cells

-   EZH2 inhibitors repress medulloblastoma growth by inducing tumor cell differentiation
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